Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022
- VernacularTitle:2020－2022年医疗机构药品行政处罚案件分析及启示
- Author:
Huiling WANG
1
;
Zhongsheng YUE
2
;
Yating QIAN
2
;
Linlin CAO
3
;
Haoxiang XIAO
3
;
Wei LIU
2
Author Information
1. School of Pharmacy，Zhengzhou Railway Vocational & Technical College，Zhengzhou 450002，China
2. College of Pharmacy，Zhengzhou University，Zhengzhou 450001，China
3. Henan Provincial Drug Evaluation and Inspection Center，Zhengzhou 450008，China
- Publication Type:Journal Article
- Keywords:
administrative penalties;
drug;
medical institutions;
inferior drugs
- From:
China Pharmacy
2023;34(21):2578-2582
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the patterns and characteristics of drug-related administrative penalty cases with medical institutions as parties from 2020 to 2022 in order to further improve drug management in medical institutions. METHODS A retrospective statistical analysis was used to summarize the drug-related administrative penalty decisions with medical institutions as parties， and to match them with the provisions of the Drug Administration Law （2019 version） for statistical analysis. RESULTS There were 144 complete administrative penalty decisions with medical institutions as parties. Analyzed by cause， 126 cases of administrative punishment for inferior drugs accounted for 87.50%， of which expired drugs accounted for more than 50.00% of the inferior drug cases； 15 cases （10.42%） were for purchasing drugs from enterprises or individuals not qualified to operate drugs. Analyzed by the range of punishment amount of the cases， 34 cases （23.61%） resulted in lighter penalties， while 81 cases （56.25%） resulted in reduced penalties. CONCLUSIONS There are extremely few medical institutions that have received administrative penalties for drug management violations. Medical institutions should strengthen the awareness of law-abiding， and know the red line of drug management and the illegal behavior that is easy to occur， so as to better strengthen drug quality management.
